Podcasts about inhibition

The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects.  Features Dr. Jack Cush, Editor at RheumNow.com.  SHOW NOTES Lupus Accelerating Breakthroughs Consortium commissioned a stakeholders group (including the FDA) to assess drug development in Cutaneous lupus CLE), and they have endorsed CLASI (CLE Dz Area & Severity Index) as the outcome measure for CLE clinical trials. https://t.co/q7If97AHBa PAPA Syndrome: When Sterile Inflammation Mimics Infection (Pyogenic Arthritis, Pyoderma gangrenosum, Acne) •A rare monogenic autoinflammatory disease •Caused by gain-of-function mutations in PSTPIP1

The Teacher's Key with Cathy Sandiford is heard each Tuesday at 12:30 PM Central Time. You can follow The Teacher's Key on Facebook here. Facebook - https://www.facebook.com/theteacherskey/ The Teacher's Key Podcast

Video Link: https://www.youtube.com/watch?v=FA1QdeuGhJEIn this whiteboard-style episode, we dive deep into the auditory brainstem response (ABR) and its profound implications for the autistic phenotype, tracing sound from the cochlea's powerful endocochlear potential through multi-step brainstem relays to the thalamus and auditory cortex. Highlighting high excitation paired with low inhibition, we map how poor filtering at key stations—like the superior olivary complex, lemniscus, and inferior colliculus—leads to listening dissonance, where sounds blend uncontrollably into overwhelming noise. The discussion underscores the mesencephalon's critical role in sensory gating, binaural processing, and the tragic risks of overload, emphasizing why compromised inhibition cascades into sensory chaos and the urgent need for understanding these upstream mechanisms.Daylight Computer Company, use "autism" for $50 off at https://buy.daylightcomputer.com/autismChroma Light Devices, use "autism" for 10% discount at https://getchroma.co/?ref=autismFig Tree Christian Golf Apparel & Accessories, use "autism" for 10% discount at https://figtreegolf.com/?ref=autismCognity AI for Autistic Social Skills, use "autism" for 10% discount at https://thecognity.com00:00 auditory processing episode: low inhibition + high excitation = sensory overload; mesencephalon key for hearing, vision, motor in autism00:55 ABR & Mesencephalon Focus Review prior ABR episode (wave 5 emphasis); mesencephalon central for toxicity phenotype sensory issues01:17 Brainstem Anatomy Slices Sliced brainstem views: medulla, pons (football shape), small mesencephalon, thalamus/subcortical above02:17 Hearing vs. Vision Pathways Hearing multi-step (cochlea → brainstem → thalamus); vision faster (retina → lateral geniculate/superior colliculus)03:21 Cochlea & Endocochlear Potential Spiral cochlea powers hearing; highest DC voltage (endocochlear potential ~+85-100mV) via potassium gradient; melanin underrated07:56 ABR Waves 2-7 Breakdown Wave 2: exiting cochlea; 3: cochlear nuclei sync; 3-4: superior olivary/lemniscus (ITD/ILD binaural, glycine/GABA inhibition); 5: inferior colliculus; 6-7: medial geniculate to A1 cortex14:17 Inferior Colliculus Role Glutamatergic excitation; binaural convergence; gamma needed for suppression (challenging in autism)17:01 Thalamus Entry & TRN Gating Wave 6: subcortical/thalamus; TRN (GABA sectors) filters sensory; compromised in autism risks overload23:20 Listening Dissonance Intro Sounds blending issue in autism; starts at olivary/lemniscus due to poor inhibition; firehose-like overload35:59 Signal-to-Noise & Prefrontal Effort High excitation/low inhibition = noise dominance; recruits medial prefrontal/ACC/insula for top-down control40:50 Overwhelm Consequences Hijacked emotional circuits (amygdala, insula); leads to shutdown/elopement; avoid talking when overwhelmed.X: https://x.com/rps47586YT: https://www.youtube.com/channel/UCGxEzLKXkjppo3nqmpXpzuAemail: info.fromthespectrum@gmail.com

In today's episode, the discussion features Joanna M. Rhodes, MD, MSCE, director of Lymphoma and systems head for Lymphoma at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, alongside Krish Patel, MD, director of Lymphoma Research and executive chair of the Lymphoma Research Executive Committee at the Sarah Cannon Research Institute. Together, they discussed how the chronic lymphocytic leukemia (CLL) treatment paradigm continues to evolve with advances in targeted therapy. In this exclusive interview, Drs Rhodes and Patel highlighted key disease- and patient-related factors that guide first-line treatment selection, considerations that influence sequencing decisions in later lines of therapy, and how hematologists determine the optimal timing to transition between treatments. They also discussed the clinical distinctions between covalent and noncovalent BTK inhibitors, the current role of pirtobrutinib (Jaypirca) in CLL management, and how its safety profile and emerging data may inform future use earlier in the treatment course. The conversation concluded with reflections on the CLL data presented at the 2025 ASH Annual Meeting that were most relevant to clinical practice. nd many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

TWiV explains studies which reveal that Inhibition of CXCL10 and IFN-γ mitgates myocarditis associated with SARS-CoV-2 mRNA vaccination, and identification of a bacteriophage T7 protein that antagonizes the DNA restriction system of the host by mimicking B form DNA. Hosts: Vincent Racaniello and Jolene Ramsey Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV ASV 2026 Understanding mRNA vaccine-associated myocarditis (Sci Transl Med) T7 protein overcomes DNA restriction of host (J Mol Biol) Structure of T7 protein that mimics DNA (Mol Cell) Letters read on TWiV 1283 Timestamps by Jolene Ramsey. Thanks! Weekly Picks Jolene – Book series Dinosaur Therapy, Dinosaur Philosophy, & Dinosaur Friendship Vincent – One Plus One Equals One: Symbiosis and the evolution of complex life by John Archibald Listener Picks Terry – Arcadia by Tom Stoppard Greg – Charctic Interactive Sea Ice Graph | National Snow and Ice Data Center Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

This is an audio version of a white broad series covering inhibition/thalamic reticular nucleus. See the video to follow along.This episode provides a detailed exploration of the thalamic reticular nucleus (TRN), the inhibitory "shell" surrounding the thalamus that acts as a sensory gate in the brain. Drawing on prior episodes, it explains how abnormalities in TRN development—linked to factors like Sonic Hedgehog signaling knockouts, reduced parvalbumin interneurons, and genes such as CNTNAP2—contribute to the excitation-inhibition imbalance central to autism. The TRN regulates sensory input access (visual, auditory, somatosensory), attention modulation, sleep-wake cycles, and overload protection; in autism, its dysfunction leads to sensory overload, hyperactivity, repetitive behaviors, and social challenges, while offering strengths like accelerated learning, intense focus, and enhanced visual thinking due to heightened inner-directed processing.83: Thalamic Reticular Nucleus (TRN), Sensory Gating & Autism https://youtu.be/cjwbog7Rk4c?si=R3Nq3Hs5A0M_7Vts 82: Sonic Hedgehog & Inhibitory Neurons in Autism https://youtu.be/Oee4L7Vsj4E?si=rG2T8R9AIYAnDBw7 76: Parvalbumin Interneurons & the Autistic Phenotype https://youtu.be/PBHVssvoQkM?si=saFvjVx9Bjq610pk Also see the Visual Thinking episodes, but White Broad Series coming to cover those in more detail.Daylight Computer Company, use "autism" for $50 off at https://buy.daylightcomputer.com/autismChroma Light Devices, use "autism" for 10% discount at https://getchroma.co/?ref=autismFig Tree Christian Golf Apparel & Accessories, use "autism" for 10% discount at https://figtreegolf.com/?ref=autismCognity AI for Autistic Social Skills, use "autism" for 10% discount at https://thecognity.com00:00 Introduction, Episode Recap, TRN Overview02:45 TRN Anatomy Drawing, Thalamus Structure and Shell05:18 Sonic Hedgehog Role, Knockout Models in Development10:48 Cell Types in TRN, Parvalbumin vs Somatostatin Functions15:19 TRN Sectors, Sensory Inputs (Visual/Auditory/Somatosensory) Access20:37 Cortical Connections, Layer 6 Feedback and Crosstalk25:04 Mini-Columns Recap, Thalamus to Layer 4 Processing29:56 Prefrontal Cortex Mapping, Adaptive Responses Role34:22 TRN Functions: Attention Modulation, Sleep-Wake Regulation36:22 CNTNAP2 Discussion, Knockout Phenotypes (Hyperactivity, Seizures)38:45 Strengths/Weaknesses: Accelerated Learning, Visual Thinking Benefits42:18 Overload Protection, Hyperactivity, Social/Repetitive Challenges46:30 Conclusion, Autism as "Self," Inner-Directed ProcessingX: https://x.com/rps47586YT: https://www.youtube.com/channel/UCGxEzLKXkjppo3nqmpXpzuAemail: info.fromthespectrum@gmail.com

This Editor's Special Episode of The HemOnc Pulse features Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discussing treatment strategies for relapsed/refractory multiple myeloma and where selinexor-based regimens fit in today's evolving landscape. Drawing from real-world cases, Dr. Richardson explores care for patients before CAR T, after CAR T relapse, and in between—highlighting how selinexor can be used flexibly across multiple lines, including as a bridge to future immunotherapies. The conversation emphasizes individualized, dynamic treatment planning to balance disease control, tolerability, and long-term goals in an increasingly complex era of myeloma care.

Carla M. Nester, MD, MSA, FASN - 2025 Congress Highlights From Houston, Texas: Translating C3G and IC-MPGN Trials to Treatment in an Era of Complement Inhibition

Commentary by Dr. Pilar Martin.

Carla M. Nester, MD, MSA, FASN - 2025 Congress Highlights From Houston, Texas: Translating C3G and IC-MPGN Trials to Treatment in an Era of Complement Inhibition

Carla M. Nester, MD, MSA, FASN - 2025 Congress Highlights From Houston, Texas: Translating C3G and IC-MPGN Trials to Treatment in an Era of Complement Inhibition

Carla M. Nester, MD, MSA, FASN - 2025 Congress Highlights From Houston, Texas: Translating C3G and IC-MPGN Trials to Treatment in an Era of Complement Inhibition

The management of hidradenitis suppurativa (HS) is evolving, but many patients still face significant hurdles in achieving optimal outcomes with current therapies. In this episode, "JAK Inhibition and the Future of HS Treatment," expert dermatologists, Hadar Lev-Tov, MD, and Jennifer L. Hsiao, MD discuss: Increasing Awareness: Debunking common myths and misconceptions about HS. Building Trust: Strategies for overcoming diagnostic delays and insufficient management. Comprehensive Care: Adopting a holistic approach, including addressing common comorbidities. The Road Ahead: Exploring the future of the HS treatment landscape, including JAK inhibition.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TEA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until December 10, 2026.Taking a New Look at Psoriatic Arthritis and Its Comorbidities Through the Lens of TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TEA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until December 10, 2026.Taking a New Look at Psoriatic Arthritis and Its Comorbidities Through the Lens of TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TEA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until December 10, 2026.Taking a New Look at Psoriatic Arthritis and Its Comorbidities Through the Lens of TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TEA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until December 10, 2026.Taking a New Look at Psoriatic Arthritis and Its Comorbidities Through the Lens of TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TEA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until December 10, 2026.Taking a New Look at Psoriatic Arthritis and Its Comorbidities Through the Lens of TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/TEA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until December 10, 2026.Taking a New Look at Psoriatic Arthritis and Its Comorbidities Through the Lens of TYK2 Inhibition In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

Starting with von Békésy's traveling wave and the cochlea's +80 mV biological battery, we move millisecond-by-millisecond through the auditory brainstem response (ABR Waves I–V), auditory nerve, cochlear nucleus, superior olivary complex, inferior colliculus, thalamic reticular nucleus, and finally primary auditory cortex (A1). The Endocochlear Potential (EP) is the highest DC voltage in the human body. As signals travel, excitation-inhibition attempts to balance that. When intact, brains can filter noise and locate meaningful sound. In Autism, reduced GABAergic sculpting (parvalbumin, somatostatin, and VIP interneuron dysfunction) plus lower myelination and a delayed Wave V — already detectable on the newborn hearing screen — turn ordinary environments into an unfiltered flood. The result is listening dissonance: a moment-to-moment perceptual struggle that collapses 40-Hz gamma, recruits massive frontal effort and emotional regions of the brain, frequently ends in sensory overload, shutdown, or literal pain. We close with the exact equation the pathway reveals: Low Inhibition + High Excitation = Sensory Overload.Daylight Computer Company, use "autism" for $50 off at https://buy.daylightcomputer.com/autismChroma Light Devices, use "autism" for 10% discount at https://getchroma.co/?ref=autismFig Tree Christian Golf Apparel & Accessories, use "autism" for 10% discount at https://figtreegolf.com/?ref=autismCognity AI for Autistic Social Skills, use "autism" for 10% discount at https://thecognity.com0:00 Chroma Light Devices and Daylight Computer Company01:56 Audition & Autism; von Békésy Traveling Wave & Tonotopy; Hair Cells & Cochlear Amplifier04:20 Endocochlear Potential (+80 mV Battery); Bioelectric Currents06:30 Stria Vascularis, Melanin, & Water Role08:15 Auditory Nerve – ABR Wave I (1.6 ms)08:36 ABR Wave II (2.7 ms)09:00 Cochlear Nucleus & Early E:I12:10 ABR Wave III – Superior Olivary Complex (3.8 ms)12:13 Binaural Processing & Calyx of Held15:00 ABR Wave V – Inferior Colliculus (5.6 ms)15:42 Inferior Colliculus Gamma & Cell Types18:00 Thalamus MGN & TRN Noise-Canceling21:30 2021 Newborn ABR Study – Prolonged Wave V Biomarker24:30 Listening Dissonance Explained28:30 Auditory Cortex Gamma Collapse in Autism32:30 Primary Auditory Cortex A1 Mini-Columns36:00 Parvalbumin, Somatostatin & VIP Interneurons39:00 Formula: Low GABA + High Excitation = Overload & PainX: https://x.com/rps47586YT: https://www.youtube.com/channel/UCGxEzLKXkjppo3nqmpXpzuAemail: info.fromthespectrum@gmail.com

Mike Sharma, MD, MSc, FRCPC - Challenging the Status Quo in Secondary Stroke Prevention: Current Perspectives on the Potential of Factor XIa Inhibition

Mike Sharma, MD, MSc, FRCPC - Challenging the Status Quo in Secondary Stroke Prevention: Current Perspectives on the Potential of Factor XIa Inhibition

In this episode of Tea with Dr D, host James Q. Del Rosso, DO, is joined by Christopher Bunick, MD, PhD, and later Lisa Swanson, MD, for a deep look at phosphodiesterase-4 (PDE4) inhibition in dermatology, with a special focus on topical roflumilast.  Dr Bunick opens with a primer on the science of PDE4, an enzyme that degrades cyclic AMP (cAMP), an intracellular messenger that regulates anti-inflammatory pathways. In conditions such as atopic dermatitis (AD) and psoriasis, overactive PDE4 leads to reduced cAMP and amplified inflammation. By “gumming up” PDE4, roflumilast restores a more balanced, anti-inflammatory state.  He explains why PDE4 inhibition is relevant across multiple inflammatory pathways, including Th1, Th2, and Th17, and why roflumilast has demonstrated stronger efficacy than earlier inhibitors like crisaborole. Molecularly, roflumilast mimics cyclic AMP's binding to PDE4 across 3 key sites, producing far tighter binding than apremilast and crisaborole, which translates to superior clinical potency.  Dr Bunick illustrates this with a case of palmoplantar pustular psoriasis that cleared dramatically within 8 weeks on topical roflumilast after multiple biologic and corticosteroid failures, highlighting its durability and barrier-restoring properties. He and Dr Del Rosso contrast this with the limitations of chronic steroid use, noting that roflumilast supports long-term control without barrier compromise.  The discussion also touches on vitiligo, where Dr Bunick shares an early case of repigmentation following roflumilast treatment, suggesting possible cAMP-mediated stimulation of melanogenesis. They highlight the molecule's innovative aqueous-based formulation, optimized for skin-compatible pH and excellent tolerability.  In Part 2, Dr Swanson joins to discuss pediatric use. She reviews the 0.15% cream for AD in patients ≥6 years and the 0.05% cream for ages 2–5, both once-daily, steroid-free options that minimize burning and stinging compared with earlier PDE4 inhibitors. They review clinical data that demonstrate rapid itch relief, strong efficacy across IGA and EASI end points, and sustained control with twice-weekly maintenance.  Tune in to hear how PDE4 inhibition, and particularly topical roflumilast, is redefining nonsteroidal therapy across age groups and disease states in dermatology. 

André, The Impulsive Thinker™, takes a practical look at inhibition and impulsivity in the ADHD Entrepreneur's daily life, reflecting on his discussion with Dr. Russell Ramsay. Ever wondered why hitting pause before reacting feels tough? It's not a flaw—it's just how your brain works. André shares real strategies that help tackle quick reactions, impulsive decisions, emotional triggers, and distractions. This episode breaks down inhibition as a skill you can build, not something you're missing. If you're ready to shift from reacting to responding in your life and business, tune in to find clarity and tools for ongoing progress, not perfection.  

Intravenous dihydropyridine calcium channel blockers can quietly worsen oxygenation by blunting hypoxic pulmonary vasoconstriction. In this episode, we break down the bedside mechanism, which agents are implicated, who's at highest risk (post-op atelectasis, obesity, pneumonia, focal ARDS, COPD), how soon it happens, and exactly what to do.The Vasopressor & Inotrope HandbookAmazon: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://amzn.to/47qJZe1⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (Affiliate Link)My Store: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://eddyjoemd.myshopify.com/products/the-vasopressor-inotrope-handbook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ (Use "podcast" to save 10%)Citations:Weir EK, López-Barneo J, Buckler KJ, Archer SL. Acute oxygen-sensing mechanisms. N Engl J Med. 2005 Nov 10;353(19):2042-55. doi: 10.1056/NEJMra050002. PMID: 16282179; PMCID: PMC2803102.Weir EK, Olschewski A. Role of ion channels in acute and chronic responses of the pulmonary vasculature to hypoxia. Cardiovasc Res. 2006 Sep 1;71(4):630-41. doi: 10.1016/j.cardiores.2006.04.014. Epub 2006 Apr 27. PMID: 16828723.Lumb AB, Slinger P. Hypoxic pulmonary vasoconstriction: physiology and anesthetic implications. Anesthesiology. 2015 Apr;122(4):932-46. doi: 10.1097/ALN.0000000000000569. PMID: 25587641.Timour G, Fréderic V, Olivier S, Shango DN. Nicardipine-induced acute respiratory failure: Case report and literature review. Clin Case Rep. 2023 May 1;11(5):e7186. doi: 10.1002/ccr3.7186. PMID: 37143457; PMCID: PMC10151601.McMurtry IF, Davidson AB, Reeves JT, Grover RF. Inhibition of hypoxic pulmonary vasoconstriction by calcium antagonists in isolated rat lungs. Circ Res. 1976 Feb;38(2):99-104. doi: 10.1161/01.RES.38.2.99. PMID: 1245025.Simonneau G, Escourrou P, Duroux P, Lockhart A. Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. N Engl J Med. 1981 Jun 25;304(26):1582-5. doi: 10.1056/NEJM198106253042606. PMID: 7231503.Kennedy T, Summer W. Inhibition of hypoxic pulmonary vasoconstriction by nifedipine. Am J Cardiol. 1982 Oct;50(4):864-8. doi: 10.1016/0002-9149(82)91246-2. PMID: 7124646.Chrétien B, Decros JB, Suard F, Dolladille C, Fischer MO, Alexandre J, Descamps R. Hypoxia Associated With Dihydropyridine Calcium Channel Inhibitors: A Pharmacovigilance Study in VigiBase. Clin Pharmacol Ther. 2023 Sep;114(3):686-692. doi: 10.1002/cpt.2970. Epub 2023 Jun 29. PMID: 37309986.Burghuber OC. Nifedipine attenuates acute hypoxic pulmonary vasoconstriction in patients with chronic obstructive pulmonary disease. Respiration. 1987;52(2):86-93. doi: 10.1159/000195309. PMID: 3671896.Suard F, Mombrun M, Fischer MO, Hanouz JL, Decros JB, Derville S, Gakuba C, Al Issa G, Menard C, Chretien B, Descamps R. Oxygenation Effects of Antihypertensive Agents in Intensive Care: A Prospective Comparative Study of Nicardipine and Urapidil. Clin Pharmacol Ther. 2025 Mar;117(3):742-748. doi: 10.1002/cpt.3509. Epub 2024 Nov 27. PMID: 39604146.

In today's episode, we had the pleasure of speaking with Kevin Kalinsky, MD, MS, FASCO, about the evolving treatment paradigm for hormone receptor (HR)–positive breast cancer post-CDK4/6 inhibition, as well as the need for more advanced therapies to improve patient outcomes in this setting. Dr Kalinsky is a professor and director in the Division of Medical Oncology of the Department of Hematology and Medical Oncology at Emory University School of Medicine, as well as the director of the Glenn Family Breast Center and the Louisa and Rand Glenn Family Chair in Breast Cancer Research at Winship Cancer Institute in Atlanta, Georgia. In our exclusive interview, Dr Kalinsky discussed combination therapies that have shown promise for the management of HR-positive breast cancer following endocrine therapy, factors influencing treatment selection for patients who have received prior CDK4/6 inhibition, best practices for genomic testing in this population, and breast cancer research highlights from the 2025 ESMO Congress.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SMF865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 7, 2026.Elevating Psoriasis and Comorbidity Management With TYK2 Inhibition: Achieving and Sustaining Outcomes to Transform Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SMF865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 7, 2026.Elevating Psoriasis and Comorbidity Management With TYK2 Inhibition: Achieving and Sustaining Outcomes to Transform Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SMF865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 7, 2026.Elevating Psoriasis and Comorbidity Management With TYK2 Inhibition: Achieving and Sustaining Outcomes to Transform Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SMF865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 7, 2026.Elevating Psoriasis and Comorbidity Management With TYK2 Inhibition: Achieving and Sustaining Outcomes to Transform Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SMF865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 7, 2026.Elevating Psoriasis and Comorbidity Management With TYK2 Inhibition: Achieving and Sustaining Outcomes to Transform Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/SMF865. CME/MOC/NCPD/AAPA/IPCE credit will be available until October 7, 2026.Elevating Psoriasis and Comorbidity Management With TYK2 Inhibition: Achieving and Sustaining Outcomes to Transform Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported through an educational grant from Bristol Myers Squibb.Disclosure information is available at the beginning of the video presentation.

Brad McGregor joins us on the heels of his #ESMO25 discussion of these important data in the NMIBC landscape.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Understanding-Endocrine-Resistance-in-HR-HER2-mBC/37323/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/PI3K-Pathway-inhibition-in-HR-HER2-mBC-Mechanistic-Insights/37329/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Comprehensive-Biomarker-Testing-in-mBC-Informs-Clinical-Decision-Making/37332/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Triple-Threat-Key-Data-on-Simultaneous-Estrogen-CDK4-6-and-PI3K-Inhibition-in-mBC/37335/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/The-Future-of-PI3K-Inhibition-in-HR-HER2-Breast-Cancer/37339/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Case-in-Point-Applying-PI3K-Combinations-in-Early-Recurrent-HR-HER2-mBC/37336/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/The-Future-of-PI3K-Inhibition-in-HR-HER2-Breast-Cancer/37339/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Triple-Threat-Key-Data-on-Simultaneous-Estrogen-CDK4-6-and-PI3K-Inhibition-in-mBC/37335/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

CME credits: 0.75 Valid until: 07-10-2026 Claim your CME credit at https://reachmd.com/programs/cme/Understanding-Endocrine-Resistance-in-HR-HER2-mBC/37323/ The PI3K-AKT-mTOR pathway is a crucial signaling network dysregulated in many cancers, promoting cell survival, growth, and proliferation, and often implicated in resistance to cancer therapies. Inhibition of this pathway by PI3K inhibitors disrupts a complex network of cellular processes that contribute to breast cancer, markedly reducing cell proliferation, promoting apoptosis, inhibiting angiogenesis, and ultimately preventing tumor formation and progression. In hormone receptor–positive (HR+), activating PIK3CA mutations occur in approximately 35% to 40% of patients and a variable prevalence across BC subtypes. Testing is thus crucial to ensure appropriate treatment selection. The development of PI3K-targeted agents may revolutionize the treatment landscape for HR+, HER2- metastatic breast cancer (mBC, and due to the recent approval of inavolisib, clinicians must be apprised of both the clinical evidence and best practices regarding the use of this agent. This activity has been designed to review the role of the PI3K-AKT-mTOR pathway in breast cancer, the importance of testing when making clinical decisions, and the role of PI3K-targeted therapies in HR+, HER- mBC.

In today's episode, we had the pleasure of speaking with Asad Dean, MD, about treatment selection for patients with chronic lymphocytic leukemia (CLL) in the second-line setting. Dr Dean is a physician at the Texas Oncology-Fort Worth Cancer Center. In our exclusive interview, Dr Dean discussed the roles of covalent BTK inhibitors and BCL-2 inhibitors in the management of CLL. He highlighted the importance of molecular profiling for treatment rechallenge decisions and the potential for resistance mutations in this disease. He also noted the role of pirtobrutinib (Jaypirca) in overcoming treatment resistance, along with clinical signs indicating that patients may need a therapy change. Dr Dean also mentioned the high response rates seen with CAR T-cell therapy in patients with CLL and explained the possibility for combination regimens in CLL. Additionally, he expressed optimism about BTK degraders and bispecific antibodies.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on IL-1 Pathway Inhibition in Recurrent Pericarditis Management: Real-World Adoption of Corticosteroid Sparing in RESONANCE.

Interview with Ehsan Rahimy, MD, author of Mammalian Target Rapamycin Inhibition as a Therapeutic Target for Prevention of Proliferative Vitreoretinopathy. Hosted by Neil Bressler, MD. Related Content: Mammalian Target Rapamycin Inhibition as a Therapeutic Target for Prevention of Proliferative Vitreoretinopathy

In today's OncClub episode, we had the pleasure of speaking with Shailee S. Shah, MD, about a retrospective study she and colleagues conducted to understand the effect of immune checkpoint inhibitors on patients with cancer and pre-existing neurologic autoimmune diseases, including multiple sclerosis, myasthenia gravis, Guillain-Barre syndrome, and Parkinson's disease. Dr Shah is a clinical assistant professor of neurology (MS/neuroimmunology) at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.  In our exclusive interview, Dr Shah discussed the design of this study, key findings, and how these results emphasize the need for multidisciplinary care and risk stratification for more effective and comprehensive patient care.  Check out the full OncClub subseries to see additional findings and insights from this research!

As we continue to learn more and more about arthrogenic muscle inhibition after ACL reconstruction surgery, we can continue to build better rehabilitation programs for our athletes.In this episode, the team discusses a recent review article on AMI and its impact on postoperative rehabilitation and return to sport decision-making.To see full show notes and more, head to: https://mikereinold.com/management-of-arthrogenic-muscle-inhibition/ Click Here to View My Online CoursesWant to learn more from me? I have a variety of online courses on my website!Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the show_____Want to learn more? Check out my blog, podcasts, and online coursesFollow me: Instagram | Twitter | Facebook | Youtube

If you've ever asked yourself, “Where should I treat first,” this is the episode for you.This episode of the Unreal Results podcast, is all about one of my favorite tools that's simple to implement and wildly effective at uncovering what's actually driving pain: inhibition tests.You've probably heard me reference inhibition tests in past episodes and today I'm breaking them down into what they are, how they work, and why they can be a game-changer in identifying hidden drivers of pain, mobility limitations, and strength loss.  You'll hear me talk about what makes a good inhibition test, why so many people get it wrong, and how this approach can take you from guessing to knowing exactly where to start treatment.Whether you'rve been using the LTAP™ for some time or just starting to question traditional orthopedic thinking, this episode will show you how to listen to the body in a whole new way and get those jaw-dropping “holy cow!” moments in your sessions.Resources Mentioned In This Episode2025 Birthday Sale! Get the savings HEREEpisode 6: The Mysterious, Misunderstood, and Mistreated SI JointEpisode 9: Left Sided Sciatica or Right Sided Shoulder Pain?Episode 16: Why The Shoulder Comes LastEpisode 54: A Better Way To Assess The SI JointEpisode 77: The Controversy of the Gillet SI Joint TestGet the book Visceral Manipulation II by Jean-Pierre BarralLearn the LTAP™ In-Person in one of my upcoming coursesThe annual birthday sale is here! From July 29th-August 1st you can save up to 60% on self-paced online education courses and the Regen library.Get the birthday sale savings HERE=================================================Watch the podcast on YouTube and subscribe!Join the MovementREV email list to stay up to date on the Unreal Results Podcast and MovementREV education. Be social and follow me:Instagram | Facebook | Twitter | YouTube

Drs. M. Ali Khan and Ajay Kuriyan join to discuss the current sentiment in the retina community regarding geographic atrophy treatment, specifically complement inhibition. Relevant Financial Disclosures: Dr. Sridhar has consulted for both Apellis and Iveric Bio in the past 3 years. You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi